Talabostat

1 paper3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: American Cancer Society and 4 more

Cells1

Outcomes

TP53BP1

downin human cells1

1 study

Talabostat decreases TP53BP1 in human cells.
“Talabostat treatment led to reductions in mean telomere length, DNA damage markers (53BP1), and telomere dysfunction-induced foci (TIFs)”
Cellsin replicative senescent human umbilical vein endothelial cells10 μM
Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells
Experimental gerontology8 Sep 2025

Latest

Experimental Gerontology11 Sep

Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells

Experiments in human cellsSenolytics

Paper

Talabostat

Outcomes

Latest

Senolytic therapy increases replicative capacity by eliminating senescent endothelial cells

Related